Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: Results of the ALL-BFM 2000 trial

Klinische Padiatrie

Volumn 225, Issue SUPPL1, 2013, Pages

  Ratei, R ^a   Schabath, R ^a   Karawajew, L ^b   Zimmermann, M ^c   Moricke A ^d   Schrappe, M ^d   Ludwig, W D ^a  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

EGIL classification; flow cytometry; immunophenotype

Indexed keywords

MYELOID ANTIGEN; PREDNISONE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIGEN EXPRESSION; ARTICLE; BIPHENOTYPIC ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL LINEAGE; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; EGIL CLASSIFICATION; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRE B LYMPHOCYTE ACUTE LYMPHOBLASTIC LEUKEMIA; PRESCHOOL CHILD; SCHOOL CHILD; SEX DIFFERENCE; T LYMPHOCYTE ACUTE LYMPHOBLASTIC LEUKEMIA;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKEMIA, BIPHENOTYPIC, ACUTE; MALE; METHOTREXATE; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 84878118960     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1337961     Document Type: Article

References (23)

1. Vardiman J. W., Thiele J., Arber D. A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood: 2009; 114 937 951
2. Craig F. E., Foon K. A. Flow cytometric immunophenotyping for hematologic neoplasms. Blood: 2008; 111 3941 3967
3. McKenna R. W., Washington L. T., Aquino D. B. et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood: 2001; 98 2498 2507
4. Pui C. H., Relling M. V., Downing J. R. Acute lymphoblastic leukemia. N Engl J Med: 2004; 350 1535 1548
5. Pui C. H., Mullighan C. G., Evans W. E. et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood: 2012; 120 1165 1174
6. Bene M. C., Castoldi G., Knapp W. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia: 1995; 9 1783 1786
7. Bene M. C., Bernier M., Casasnovas R. O. et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood: 1998; 92 596 599 (Pubitemid 28323723)
8. Moricke A., Zimmermann M., Reiter A. et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia: 2010; 24 265 284
9. Moricke A., Reiter A., Zimmermann M. et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood: 2008; 111 4477 4489
10. Matutes E., Pickl W. F., Van't Veer M. et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood: 2011; 117 3163 3171
11. Gerr H., Zimmermann M., Schrappe M. et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol: 2010; 149 84 92
12. Schott G., Sperling C., Schrappe M. et al. Immunophenotypic and clinical features of T-cell receptor gammadelta+ T-lineage acute lymphoblastic leukaemia. Br J Haematol: 1998; 101 753 755 (Pubitemid 28308527)
13. Ng S. M., Ariffin W. A., Lin H. P. et al. Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children. J Trop Pediatr: 2000; 46 73 78 (Pubitemid 30232541)
14. Putti M. C., Rondelli R., Cocito M. G. et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood: 1998; 92 795 801 (Pubitemid 28355462)
15. Lawlor E. Myeloid antigen expression in childhood acute lymphoblastic leukemia. Br J Haematol: 1992; 80 566
16. Wiersma S. R., Ortega J., Sobel E. et al. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med: 1991; 324 800 808
17. Drexler H. G. Myeloid-antigen expression in adult acute lymphoblastic leukemia. N Engl J Med: 1987; 317 1156 1157
18. Pui C. H., Behm F. G., Singh B. et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood: 1990; 75 198 202 (Pubitemid 20031509)
19. Drexler H. G., Thiel E., Ludwig W. D. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia: 1991; 5 637 645
20. Brunning R. D., Matutes E., Borowitz M. J. Acute Leukemias of Ambiguous Lineage. IARC Press Lyon, France: 2001
21. Borowitz M. J., Bene M. C., Harris N. L. et al. Acute leukaemias of ambiguous lineage. IARC Press Lyon, France: 2008
22. EGIL The value of c-kit in the diagnosis of biphenotypic acute leukemia. EGIL (European Group for the Immunological Classification of Leukemias). Leukemia: 1998; 12 2038
23. Mejstrikova E., Volejnikova J., Fronkova E. et al. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica: 2010; 95 928 935.